Illana Schlam

What We Will Discuss:

• Overview of Personalis and high-level recent clinical evidence
• Integration of MRD in clinical trial development
• Regulatory and quality hurdles for ultra-high sensitivity assays

This collaborative session brings together industry leaders to discuss the integration of ctDNA monitoring into clinical trial development. Panellists will share their organizational strategies, implementation experiences, key opportunities, and internal adoption efforts. The Engager will also cover key opportunities to accelerate adoption, strategies for securing leadership alignment, and how Personalis can support these initiatives. Attendees will gain real-world insights into regulatory frameworks, academic requirements, and biotech perspectives, while also exploring how Personalis can further support pharma’s ctDNA integration goals.